StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Marker Therapeutics (MRKR)

Wed, 20 May 2026 06:49:15 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $10.00 price target on Marker Therapeutics (NASDAQ: MRKR).

The analyst commented: "Marker reported 1Q26 financial results on May 15. The quarter was not thesis-changing, but it was supportive of the catalyst setup into 2Q26, in our view, as Marker maintained tight cost control, reported just $1.4 million of operating cash use, and exited 1Q26 with $15.6 million in cash, cash equivalents, and restricted cash, supporting runway into 1Q27 assuming no additional grant funds are received. The key stock debate remains clinical and regulatory: whether MT-601 can move from the Phase 1

Form 10-Q Marker Therapeutics, For: Mar 31

Fri, 15 May 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26507513.html

Form 10-Q Marker Therapeutics, For: Mar 31

Fri, 15 May 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26507513.html

Form 8-K Marker Therapeutics, For: May 01

Mon, 04 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260504/26426368.html

Form 8-K Marker Therapeutics, For: May 01

Mon, 04 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260504/26426368.html

H.C. Wainwright Reiterates Buy Rating on Marker Therapeutics (MRKR)

Mon, 23 Mar 2026 06:48:08 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $10.00 price target on Marker Therapeutics (NASDAQ: MRKR).

The analyst commented: "On Mar 18, Marker reported 4Q25 and 2025 financial results and provided a corporate update on its multi-antigen recognizing T cell (MAR-T) pipeline—a non-genetically modified autologous T cell therapy product targeting multiple tumor-associated antigens (TAAs). Importantly, the upcoming meeting with the FDA anticipated expected in 2Q26 (around April according to our January meeting with management) is the primary gating factor for Marker’s transition towards pivotal-stage. Marker plans to discuss the details for the planned pivotal Phase 2b study to evaluate

Form DEFA14A Marker Therapeutics,

Fri, 20 Mar 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260320/26197796.html

Form DEFA14A Marker Therapeutics,

Fri, 20 Mar 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260320/26197796.html

Form ARS Marker Therapeutics, For: Dec 31

Fri, 20 Mar 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260320/26197780.html

Form ARS Marker Therapeutics, For: Dec 31

Fri, 20 Mar 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260320/26197780.html

Form DEF 14A Marker Therapeutics, For: May 01

Fri, 20 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260320/26197744.html

Form DEF 14A Marker Therapeutics, For: May 01

Fri, 20 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260320/26197744.html

Form 8-K Marker Therapeutics, For: Mar 18

Thu, 19 Mar 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260319/26188455.html

Form 8-K Marker Therapeutics, For: Mar 18

Thu, 19 Mar 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260319/26188455.html

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results